Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Pharmacological and dietary inhibition of a novel metabolic-epigenetic crosstalk in head and neck cancer

Award Number: R01DE033648
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2029

Group Awards By:

View Award Description

Pharmacological and dietary inhibition of a novel metabolic-epigenetic crosstalk in head and neck cancer - PROJECT SUMMARY Head and Neck Squamous Cell Carcinoma (HNSCC) is an aggressive malignancy derived from stratified squamous epithelium of the oral cavity. Leukoplakia is a premalignant condition and is recognized as the precursor lesion of HNSCC. During leukoplakia-associated neoplastic evolution, benign squamous epithelium first becomes dysplasia, then carcinoma in situ, and finally progresses to invasive SCC. Therefore, leukoplakia serves as an ideal premalignant model for the investigation of the step-wise neoplastic evolution of oral squamous epithelial cells. However, our understanding of the molecular mechanisms promoting leukoplakia- associated neoplasia remains quite limited. This shortcoming is largely due to viable and valid human models representing this unique pathological transition have been lacking. To address this key challenge, we have developed two independent, cross-species organoid systems modeling the step-wise neoplastic evolution of HNSCC. Both metabolic reprogramming and epigenomic deregulation are cancer hallmarks. Here we have mapped a key mechanistic crosstalk between the methionine cycle and epigenomic reprogramming, through a novel cascade involving LAT1-methionine-EZH2. Specifically, we find that HNSCC exhibits the highest activity of this cascade among all human cancers. High LAT1 expression correlates with poor survival of HNSCC patients. Importantly, this cascade is indispensable for the survival and proliferation of HNSCC cells, representing a tumor-specific vulnerability. Notably, this novel LAT1-methionine-EZH2 cascade can be targeted by either pharmacological approaches or dietary intervention. These interesting and significant findings prompt us to hypothesize that the novel LAT1-methionine-EZH2 cascade functionally promotes both early precursor transformation and cancer development, representing a prominent actionable target for cancer prevention and treatment. To test this hypothesis, we will leverage our versatile premalignant and tumor organoid systems as well as animal models, to investigate the biological significance of the LAT1-methionine-EZH2 cascade during both the initial steps of oral neoplastic transformation and fully-established HNSCC tumors. We will establish the molecular basis of this pathway using advanced metabolomic profiling and epigenomic approaches such as Cut&Tag. We will perform preclinical evaluation of pharmacological and dietary blockade of this cascade, to rigorously assess both tumor-prevention and tumor-killing effect of candidate approaches. We will further develop LAT1-high vs LAT1-low organoid models to investigate whether LAT1 serves as a biomarker to predict cellular dependence on the LAT1-methionine-EZH2 axis. This study not only investigates fundamental cancer biology, but also has significant translational implications for both early intervention and treatment of HNSCC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $497,650 )
2026	2026	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Oral Diseases and Disorders Research	001	3	4/16/2026	NON-COMPETING CONTINUATION	$49,765
2026	2026	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Oral Diseases and Disorders Research	000	3	1/30/2026	NON-COMPETING CONTINUATION	$447,885
														Subtotal = $497,650

Issue Date FY: 2025 ( Subtotal = $497,650 )
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Oral Diseases and Disorders Research	000	2	4/17/2025	NON-COMPETING CONTINUATION	$447,885
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Oral Diseases and Disorders Research	001	2	5/7/2025	NON-COMPETING CONTINUATION	$49,765
														Subtotal = $497,650

Issue Date FY: 2024 ( Subtotal = $497,275 )
2024	2024	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90089	LOS ANGELES	USA	Oral Diseases and Disorders Research	000	1	2/27/2024	NEW	$497,275
														Subtotal = $497,275

Grand Total All Awards = $1,492,575

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pharmacological and dietary inhibition of a novel metabolic-epigenetic crosstalk in head and neck cancer

Award Number: R01DE033648

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer